Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide consolidation plus rituximab maintenance in relapsed follicular lymphoma stratified by post-induction PET status
ACTRN12613000106730Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide and rituximab in follicular lymphoma (FL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: PET conversion from positive to negative after 6 months. Started Nov 2013; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12613000106730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000106730.